20:15 , Aug 11, 2017 |  BC Week In Review  |  Clinical News

Avelas starts Phase II of imaging agent AVB-620 in patients with primary breast cancer

Avelas Biosciences Inc. (La Jolla, Calif.) began a Phase II trial to evaluate a single dose of IV AVB-620 administered prior to surgery to detect malignant tissue in about 100 women with primary, non-recurrent, non-metastatic...
00:41 , Feb 3, 2017 |  BC Week In Review  |  Clinical News

AVB-620: Ph Ib data

Data from about 15 patients with primary, non-recurrent breast cancer undergoing surgery in an open-label, dose-escalation, U.S. Phase Ib trial showed that a single dose of IV AVB-620 administered prior to surgery led to no...
07:00 , Aug 18, 2016 |  BC Extra  |  Financial News

Avelas' series C round brings in $20M

Avelas Biosciences Inc. (La Jolla, Calif.) raised $20 million in a series C financing led by the Pharmstandard International S.A. subsidiary of Pharmstandard OJSC (RTS:PHST; LSE:PHST). New investors Ervington Investments and Alexandria Venture Investments participated,...
08:00 , Nov 16, 2015 |  BC Week In Review  |  Clinical News

AVB-620: Phase I started

Avelas began an open-label, dose-escalation, U.S. Phase I trial to evaluate single doses of IV AVB-620 in up to 39 patients with stage I-III breast cancer prior to surgery. Avelas Biosciences Inc., La Jolla, Calif....